A. te Velde

2.4k total citations · 1 hit paper
11 papers, 1.8k citations indexed

About

A. te Velde is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. te Velde has authored 11 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. te Velde's work include Cancer therapeutics and mechanisms (4 papers), Cancer survivorship and care (4 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). A. te Velde is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), Cancer survivorship and care (4 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). A. te Velde collaborates with scholars based in Netherlands, Germany and Greece. A. te Velde's co-authors include Neil K. Aaronson, Mirjam A. G. Sprangers, Babs G. Taal, A. Cull, M. Groenvold, Hanneke C. de Haes, Marianne Müller, Anna-leila Williams, Jeremy D. Franklin and Juan Ignacio Arrarás and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

A. te Velde

10 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.

1996 892 citations Mirjam A. G. Sprangers, M. Groenvold et al. Journal of Clinical Oncology profile →

Peers

A. te Velde

ONCOL

SURGE

PRM

CR

PPCH

E. Wist Norway

W D George United Kingdom

Peter Grimison Australia

C Stegmaier Germany

T.J. Priestman United Kingdom

D. Dalley Australia

MA Richards United Kingdom

Thomas E. Lad United States

David Wyld Australia

L Deschênes Canada

E. Wist Norway

A. te Velde

1.1k ×0.8

ONCOL

611 ×0.9

SURGE

384 ×1.2

PRM

292 ×1.2

CR

365 ×1.8

PPCH

Citations per year, relative to A. te Velde A. te Velde (= 1×) peers E. Wist

Countries citing papers authored by A. te Velde

Since Specialization

Citations

This map shows the geographic impact of A. te Velde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. te Velde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. te Velde more than expected).

Fields of papers citing papers by A. te Velde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. te Velde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. te Velde. The network helps show where A. te Velde may publish in the future.

Co-authorship network of co-authors of A. te Velde

This figure shows the co-authorship network connecting the top 25 collaborators of A. te Velde. A scholar is included among the top collaborators of A. te Velde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. te Velde. A. te Velde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Sprangers, Mirjam A. G., A. te Velde, & Neil K. Aaronson. (1999). The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Journal of Cancer. 35(2). 238–247. 415 indexed citations

2.

Brink, Mirjam van den, et al.. (1997). 2104 Analysis of dose volume histogram parameters to estimate late bladder and rectum complications after high-dose (70–78 Gy) conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology*Biology*Physics. 39(2). 292–292.

3.

Catimel, G., Steinar Aamdal, W ten Bokkel Huinink, et al.. (1996). Phase II clinical trials with rhizoxin in breast cancer and melanoma. British Journal of Cancer. 73(3). 397–399. 27 indexed citations

4.

Verweij, Jaap, J. Wanders, Thierry Gil, et al.. (1996). Phase II study of rhizoxin in squamous cell head and neck cancer. British Journal of Cancer. 73(3). 400–402. 13 indexed citations

5.

Pavlidis, Nicholas, Axel‐R. Hanauske, Teresa Gamucci, et al.. (1996). A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC Early Clinical Studies Group (ECSG). Annals of Oncology. 7(5). 529–531. 37 indexed citations

6.

Sprangers, Mirjam A. G., M. Groenvold, Juan Ignacio Arrarás, et al.. (1996). The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.. Journal of Clinical Oncology. 14(10). 2756–2768. 892 indexed citations breakdown →

7.

Dirix, Luc, Jim Cassidy, Ron Epelbaum, et al.. (1996). EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. European Journal of Cancer. 32(11). 2019–2022. 45 indexed citations

8.

Kaplan, Steven, A.-R. Hanauske, N. Pavlidis, et al.. (1996). Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group. British Journal of Cancer. 73(3). 403–405. 20 indexed citations

9.

Velde, A. te, M. A. G. Sprangers, & Neil K. Aaronson. (1996). Feasibility, psychometric performance, and stability across modes of administration of the CARES-SF. Annals of Oncology. 7(4). 381–390. 32 indexed citations

10.

Velde, A. te, et al.. (1996). 1005 High-dose (70–78 GY) conformal radiotherapy for prostate cancer; the relation between observed late bladder and rectum complications and parameters derived from the dose volume histograms. International Journal of Radiation Oncology*Biology*Physics. 36(1). 246–246. 6 indexed citations

11.

Sprangers, Mirjam A. G., Babs G. Taal, Neil K. Aaronson, & A. te Velde. (1995). Quality of life in colorectal cancer. Diseases of the Colon & Rectum. 38(4). 361–369. 355 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact